Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancer
RLMD•Safety results
Safety update: no Grade 3 or higher treatment-related adverse events; 63% reported treatment-related events, mainly dysuria at 54%.
Development plan
Development plan targets IND filings by year-end 2026 for NDV-01 and sepranolone; Phase 3 RESCUE registrational cohorts start upon IND clearance.
Phase 2a TRCG-011 efficacy update
Ongoing Phase 2a TRCG-011 high-risk NMIBC study showed 95% anytime complete response; 76% complete response at 12 months.
The BCG-unresponsive subgroup showed 94% anytime complete response; 80% complete response at 12 months; no progression to muscle-invasive disease.
Investor presentation highlights NDV-01 program
Relmada outlined NDV-01 as its lead program, a sustained-release intravesical gemcitabine/docetaxel candidate for non-muscle invasive bladder cancer.
